Abstract

The World Health Organization (WHO) has declared the outbreak of 2019 novel coronavirus, known as 2019-nCoV, a pandemic, as the coronavirus has now infected over 2.6 million people globally and caused more than 185,000 fatalities as of April 23, 2020. Coronavirus disease 2019 (COVID-19) causes a respiratory illness with symptoms such as dry cough, fever, sudden loss of smell, and, in more severe cases, difficulty breathing. To date, there is no specific vaccine or treatment proven effective against this viral disease. Early and accurate diagnosis of COVID-19 is thus critical to curbing its spread and improving health outcomes. Reverse transcription-polymerase chain reaction (RT-PCR) is commonly used to detect the presence of COVID-19. Other techniques, such as recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), clustered regularly interspaced short palindromic repeats (CRISPR), and microfluidics, have allowed better disease diagnosis. Here, as part of the effort to expand screening capacity, we review advances and challenges in the rapid detection of COVID-19 by targeting nucleic acids, antigens, or antibodies. We also summarize potential treatments and vaccines against COVID-19 and discuss ongoing clinical trials of interventions to reduce viral progression.

Highlights

  • The recent global outbreak of COVID-19 has led to a public health emergency

  • COVID-19 can spread from person-to-person and animal, and transmission of infection may occur with exposure to symptomatic patients or asymptomatic individuals

  • Previous coronavirus epidemics like SARS and MERS have expedited the process of finding useful diagnostic and therapies against 2019-nCoV

Read more

Summary

Introduction

The recent global outbreak of COVID-19 has led to a public health emergency. As of April 23, 2020, over 2.6 million confirmed cases were reported to WHO from 213 countries and territories [1]. With the rapid increase in the number of confirmed cases, WHO classified the global COVID-19 outbreak as a pandemic on March 11, 2020 [3]. A transmembrane glycoprotein, CD147, known as Basigin or EMMPRIN, has been confirmed as another receptor for binding of the 2019-nCoV S protein, thereby mediating viral invasion [18]. A confirmed case should have at least one of the following criteria: (i) a positive result for 2019-nCoV nucleic acid, using real-time PCR tests from respiratory or blood samples; (ii) a high homogeneity between viral gene sequencing from respiratory or blood samples and known 2019-nCoV; and (iii) serum samples positive for IgM or IgG to 2019-nCoV, or seroconversion in IgG, or a fourfold or more significant increase in IgG antibody titer to 2019-nCoV in the recovery phase than in the acute phase [25]

Nucleic Acid Targeting
BIP B1C
Sampling methods
Medical Treatment
Control and Prevention of COVID-19
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call